Real-World Impact of TV-44749 in Adults With Schizophrenia (RADIANCE)

Study Title
Real-World Impact of Subcutaneous Long-Acting Injectable Olanzapine Suspension (TV-44749) in Adult Patients With Schizophrenia: RADIANCE Study
Teva Identifier
TV44749-CNS-40299
ClinicalTrials.gov Identifier
NCT07913100
Study Status
Not yet recruiting
Trial Condition(s)
Schizophrenia
Interventions
Drug: TV-44749
Study Description
Please refer to ClinicalTrials.gov for a description of the trial
brain-icon

Key Participation Requirements

Gender
Female, Male
Age group
Adult, Older Adult
Age Range
18 Years and older
Trial Duration
March 30, 2027 - May 31, 2031
Phase
4

Study Type

Observational